Elevation Point Wealth Partners LLC Boosts Stock Position in Astrazeneca Plc $AZN

Elevation Point Wealth Partners LLC increased its holdings in Astrazeneca Plc (NYSE:AZN) by 212.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,217 shares of the company’s stock after purchasing an additional 30,746 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Astrazeneca were worth $8,914,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Natixis Advisors LLC increased its stake in shares of Astrazeneca by 14.3% during the third quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock valued at $161,142,000 after buying an additional 262,465 shares during the period. Guardian Capital LP raised its holdings in shares of Astrazeneca by 31.0% during the third quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock valued at $6,373,000 after acquiring an additional 19,648 shares in the last quarter. Legacy Capital Group California Inc. purchased a new stake in Astrazeneca in the third quarter worth $406,000. Focus Partners Advisor Solutions LLC boosted its holdings in Astrazeneca by 53.8% in the third quarter. Focus Partners Advisor Solutions LLC now owns 10,307 shares of the company’s stock valued at $875,000 after acquiring an additional 3,604 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its holdings in Astrazeneca by 50.0% in the third quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $23,016,000 after acquiring an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

AZN stock opened at $194.96 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a 50 day moving average price of $183.91 and a 200-day moving average price of $187.76. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The firm has a market capitalization of $302.36 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Equities research analysts forecast that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Wall Street Analysts Forecast Growth

AZN has been the subject of several research reports. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.